REFERENCES
REFERENCES
- Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors. 2013;39(1):2-13.
- Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787-809.
- Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103(11):1545-1557.
- Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16(6):4567-4598.
- Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9):1010-1030.
- Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76(11):1590-1611.
- Lindstrom A, Ooyen C, Lynch ME, Blumenthal M. Herb supplement sales increase 5.5% in 2012. HerbalGram. 2013;99:60-64.
- Lindstrom A, Ooyen C, Lynch ME, Blumenthal M, Kawa K. Sales of herbal dietary supplements increase by 7.9% in 2013, marking a decade of rising sales. HerbalGram. 2014;103:52-56.
- Smith T, Lynch ME, Johnson J, Kawa K, Bauman H, Blumenthal M. Herbal dietary supplement sales in US increase 6.8% in 2014. HerbalGram. 2015;107:52-59.
- 10a. Smith T, Kawa K, Eckl V, Johnson J. Sales of herbal dietary supplements in US increased 7.5% in 2015. HerbalGram. 2016;111:67-73.
10b. Smith T, Kawa K, Eckl V, Morton C, Stredney R. Herbal supplement sales in US increased 7.7% in 2016. HerbalGram. 2017;115:56-65.
10c. Smith T, Kawa K, Eckl V, Morton C, Stredney R. Herbal supplement sales in US increased 8.5%in 2017. HerbalGram. 2018;119:62-71. - International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2). Geneva, Switzerland: International Conference on Harmonisation (ICH); February 6, 2003. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed March 4, 2016.
- Nagpal M, Sood S. Role of curcumin in systemic and oral health: An overview. J Nat Sci Biol Med. 2013;4(1):3-7.
- Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, Vered M. Nutraceuticals as new treatment approaches for oral cancer – I: Curcumin. Oral Oncol. 2013;49(3):187-191.
- Wang LL, Sun Y, Huang K, Zheng L. Curcumin, a potential therapeutic candidate for retinal diseases. Mol Nutr Food Res. 2013;57(9):1557-1568.
- Zingg JM, Hasan ST, Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 2013;39(1):101-121.
- Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys. 2012;49(5):306-315.
- Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. 2013;39(2):197-208.
- Meng B, Li J, Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des. 2013;19(11):2101-2113.
- Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012;85(4):249-255.
- Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food Funct. 2012;3(11):1109-1117.
- Monroy A, Lithgow GJ, Alavez S. Curcumin and neurodegenerative diseases. Biofactors. 2013;39(1):122-132.
- Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol. 2012;26(12):1512-1524.
- Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919-930.
- Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10. doi: 10.1186/1472-6882-6-10.
- Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719-1725.
- Das AD, Balan A, Sreelatha KT. Comparative study of the efficacy of curcumin and turmeric oil as chemopreventive agents in oral submucous fibrosis: A clinical and histopathological evaluation. Journal of Indian Academy of Oral Medicine and Radiology. 2010;22(2):88-92.
- Sanmukhani J, Satodia V, Trivedi J et al. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytother Res 2014 Apr;28(4):579-85 .
- Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368-375.
- Hejazi J, Rastmanesh R, Taleban F-A, Molana S-H, Ehtejab G. A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer. J Cancer Sci Ther. 2013;5(10):320-324.
- Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110-113.
- Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007;56(6):509-514.
- Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J Affect Disord. 2017;207:188-196.
- Rainey-Smith SR, Brown BM, Sohrabi HR et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr. 2016;115(12)2106-2113.
- Hejazi J, Rastmanesh R, Taleban FA, et al. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: a double blinded, randomized, placebo-controlled study. Nutr Cancer. 2016;68(1):77-85.
- Wichtl M, ed. Brinckmann JA, Lindenmaier MP, trans. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis. 3rd ed. Stuttgart, Germany: medpharm GmbH Scientific Publishers; 2004.
- Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. 2nd ed. Paris, France: Lavoisier Publishing; 1999.
- Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(2):1867-1876.
- Gordon ON, Schneider C. Vanillin and ferulic acid: not the major degradation products of curcumin. Trends Mol Med. 2012;18(7):361-363.
- Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1411-1417.
- Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011;108(16):6615-6620.
- Liju VB, Jeena K, Kuttan R. An evaluation of antioxidant, anti-inflammatory, and antinociceptive activities of essential oil from Curcuma longa. L. Indian J Pharmacol. 2011;43(5):526-531.
- Yue GG, Chan BC, Hon PM, et al. Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa. Food Chem Toxicol. 2010;48(8-9):2011-2020.
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356. doi: 10.1055/s-2006-957450.
- Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
- Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847-6854.
- Goindi S, Maheshwari M. Comparative bioavailability of curcumin, turmeric and Biocurcumax™ in traditional vehicles using non-everted rat intestinal sac model. J Funct Foods. 2010;2(1):60-65.
- Antony B, Benny M, Rao S. Enhancing the absorption of curcuminoids. Spice India. July 2005:23-26.
- Butchin R. Bioavailability of a novel, bioenhanced preparation of curcumin in dogs. Poster presented at: 2009 ACVIM Forum/Canadian Veterinary Medical Association Convention; June 3-6, 2009; Montréal, Québec, Canada.
- Benny M, Antony B. Bioavailability of Biocurcumax (BCM-95). Spice India. September 2006:11-15.
- Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008;70(4):445-449.
- Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J. 2014;13:11. doi: 10.1186/1475-2891-13-11.
- Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY. Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol. 2012;51(4):515-525.
- Shen LR, Parnell LD, Ordovas JM, Lai CQ. Curcumin and aging. Biofactors. 2013;39(1):133-140.
- Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine. 2005;12(6-7):445-452.
- Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661.
- Brunswick Labs. ORAC assay results BCM 95 Soft Gel Grade lot #SG/0607/B11. August 11, 2006.
- Brunswick Labs. ORAC assay results BCM 95 lot #CG/0607/B11. January 31, 2007.
- Kumar S, Sriman V, Shashank M, Alaparthi V, Choudhard Y. Anti-inflammatory activity of a herbal formulation (BCM-95) and Curcuma longa extract: a comparative dose response study. 2013. (Unpublished)
- Leray V, Freuchet B, Le Bloc’h J, Jeusette I, Torre C, Nguyen P. Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. Br J Nutr. 2011;106(Suppl S1):S198-S201.
- Horohov DW, Sinatra ST, Chopra RK, Jankowitz S, Betancourt A, Bloomer RJ. The effect of exercise and nutritional supplementation on proinflammatory cytokine expression in young racehorses during training. J Equine Vet Sci. 2012;32(12):805-815.
- Shakibaei M, Buhrmann C, Kraehe P, Shayan P, Lueders C, Goel A. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS One. 2014;9(1):e85397. doi: 10.1371/journal.pone.0085397.
- Buhrmann C, Kraehe P, Lueders C, Shayan P, Goel A, Shakibaei M. Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT. PLoS One. 2014;9(9):e107514. doi: 10.1371/journal.pone.0107514.
- Shakibaei M, Kraehe P, Popper B, Shayan P, Goel A, Buhrmann C. Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer. 2015;15:250. doi: 10.1186/s12885-015-1291-0.
- Toden S, Okugawa Y, Jascur T, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 2015;36(3):355-367.
- Toden S, Okugawa Y, Buhrmann C, et al. Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev Res (Phila). 2015;8(5):431-443.
- Siddappa G, Kulsum S, Ravindra DR. Chemoprevention and treatment efficacy of curcumin in combination with metformin in an in vivo oral carcinogenesis model. Poster presented at: 5th IFHNOS World Congress 2014; July 26-30, 2014; New York, New York.
- Sanmukhani J, Anovadiya A, Tripathi CB. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol Pharm. 2011;68(5):769-775.
- Anovadiya AP, Sanmukhani JJ, Vadgama VK, Tripathi CB. Evaluation of antiepileptic and memory retention activity of curcumin per se and in combination with antiepileptic drugs. Asian J Pharm Clin Res. 2013;6(Suppl 2):145-148.
- Sudhakaran PR. Biocurcumax in carbon tetrachloride induced liver injury. Kariavattom, Kerala, India: University of Kerala; 2010.
- Sudhakaran PR. Biocurcumax in alcohol induced liver injury. Kariavattom, Kerala, India: University of Kerala;2010.
- Lopresti AL, Maes M, Meddens MJ, Maker GL, Arnoldussen E, Drummond PD. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur Neuropsychopharmacol. 2015;25(1):38-50.
- Antony B, Kizhakedath R, Benny M, Kuruvilla BT. 316 Clinical evaluation of a herbal formulation, Rhulief™, in the management of knee osteoarthritis. Osteoarthritis Cartilage. 2011;19(Suppl 1):S145-S146.
- Gardner Z, McGuffin M, eds. American Herbal Products Association’s Botanical Safety Handbook. 2nd ed. Boca Raton, Florida: CRC Press; 2013.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis, Missouri: Elsevier; 2005.
- National Cancer Institute. Clinical development plan: Curcumin. J Cell Biochem. 1996;63(Suppl S26):72-85.
- Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res. 2001;7(5):1452-1458.
- Perkins S, Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002;11(6):535-540.
- Ganiger S, Malleshappa HN, Krishnappa H, Rajashekhar G, Ramakrishna Rao V, Sullivan F. A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. Food Chem Toxicol. 2007;45(1):64-69.
- Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511-545.
- Kim DC, Ku SK, Bae JS. Anticoagulant activities of curcumin and its derivative. BMB Rep. 2012;45(4):221-226.
- Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008;36(8):1594-1605.
- Chen Y, Liu WH, Chen BL, et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother. 2010;44(6):1038-1045.
- Juan H, Terhaag B, Cong Z, et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol. 2007;63(7):663-668.
- Shriram Institute for Industrial Research. Acute Oral Toxicity Study in Mice. Report No. 00217109. November 7, 2011.
- Shriram Institute for Industrial Research. Acute Oral Toxicity Study in Rats. Report No. 00217109. November 7, 2011.
- Sudhakaran PR. Biocurcumax (BCM-95) subchronic toxicity in rats. Alwaye, Kerala, India: Arjuna Natural Extracts Ltd.; 2010.
- Shriram Institute for Industrial Research. 90 Days Repeated Dose Oral Toxicity Study in Rats. Report No. 00217110. November 7, 2011.
- Shriram Institute for Industrial Research. Mammalian Bone Marrow Chromosome Aberration Test. Report No. 00217109. November 7, 2011.
- Shriram Institute for Industrial Research. Ames Test (Bacterial Reverse Mutation Assay). Report No. 00217109. November 7, 2011.
- GRAS Notices: GRN No. 686. Curcumin from turmeric (Curcuma longa L.). US Food & Drug Administration website. Available at: www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=686&sort=GRN_No&order=DESC&startrow=1&type=basic&search=curcumin. Accessed November 13, 2017.